Ernexa Therapeutics Inc. (ERNA): who owns it and who trades it
As of Nov 10, 2026, ERNA insiders reported 1 purchase worth $2M in the last 12 months. The largest buyer was Charles Cherington (10% owner), with $2M.
Latest filing Nov 10, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, ERNA insiders reported $2M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | Charles Cherington | 10% owner | Purchase | 4.00M | $0.50 | $2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Charles Cherington | 10% owner | $2M | – | Feb 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ERNA short interest
Low short interest. 2.0% of ERNA shares are sold short: about 1 share in 49. Over the last 12 reports the number of shares short went down 80%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 33,263 ERNA shares were sold short, 2.0% of the shares outstanding, up 67.3% from the report before. At the average daily volume of 16,424 shares, buying them all back would take about 2.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 33,263 | 2.04% | +67% | 16,424 | 2.0 |
| Oct 15, 2026 | 19,877 | 1.22% | +1% | 105,857 | 1.0 |
| Sep 30, 2026 | 19,725 | 1.21% | +37% | 23,717 | 1.0 |
| Sep 15, 2026 | 14,361 | 0.88% | -27% | 69,218 | 1.0 |
| Aug 31, 2026 | 19,798 | 1.21% | -20% | 36,104 | 1.0 |
| Aug 14, 2026 | 24,656 | 1.51% | +69% | 47,948 | 1.0 |
| Jul 31, 2026 | 14,605 | 0.05% | -1% | 111,110 | 1.0 |
| Jul 15, 2026 | 14,740 | 0.05% | -50% | 2.48M | 1.0 |
| Jun 30, 2026 | 29,381 | 0.10% | -28% | 69,259 | 1.0 |
| Jun 15, 2026 | 40,604 | 0.14% | -9% | 45,433 | 1.0 |
| May 29, 2026 | 44,811 | 0.15% | -72% | 99,259 | 1.0 |
| May 15, 2026 | 162,618 | 0.56% | +22% | 8.82M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Ernexa Therapeutics company events
Ernexa Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Oct 15, 2026.
- Oct 15, 2026AnnouncementShared information with investors. Filing
- Sep 16, 2026AnnouncementShared information with investors. Filing
- Sep 16, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee of the board of directors of Ernexa Therapeutics Inc., a Delaware corporation approved the appointment of Robert J. Spiegel, M.D. to serve as a member of the Board, effective immediately. Filing
- Jul 2, 2026AnnouncementShared information with investors. Filing
- Jul 2, 2026VoteReported shareholder vote results. Filing
- Jun 26, 2026LeadershipSandra Gurrola, Senior Vice President of Finance of Ernexa Therapeutics Inc., a Delaware corporation, delivered her notice of resignation, with such resignation becoming effective July 3, 2026. Filing
- May 4, 2026RulesChanged its bylaws or articles. Filing
- Mar 20, 2026ListingErnexa Therapeutics Inc., a Delaware corporation, received a written notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Nasdaq staff determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30… Filing
- Feb 26, 2026AnnouncementShared information with investors. Filing
- Feb 11, 2026AgreementErnexa Therapeutics Inc., a Delaware corporation, entered into a placement agency agreement with Brookline Capital Markets, a division of Arcadia Securities, LLC, pursuant to which the Company engaged the Placement Agent as the placement agent for the public offering of (i) 19,000,000 shares of the… Filing
- Dec 11, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ernexa Therapeutics financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ERNA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | Bleichroeder LP | 13G/A | 4.7% |
| Nov 10, 2026 | Bleichroeder LP | 13G/A | 4.7% |
| Oct 30, 2026 | Freebird Partners LP | 13G/A | 7.0% |
| Oct 30, 2026 | Freebird Partners LP | 13G/A | 7.0% |
Questions about Ernexa Therapeutics Inc. (ERNA) stock
Are ERNA insiders buying or selling?
In the last 12 months, ERNA insiders reported 1 open-market purchase worth $2M and no sales. The latest trade was on Feb 10, 2026. See every trade.
What is the short interest in ERNA?
As of Oct 30, 2026, 33,263 ERNA shares were sold short, 2.0% of the shares outstanding, up 67.3% from the report before. At the average daily volume of 16,424 shares, buying them all back would take about 2.0 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.